{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:31:04Z","timestamp":1792499464440,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[1993,12,1]],"date-time":"1993-12-01T00:00:00Z","timestamp":754704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1993,12]]},"DOI":"10.1007\/bf00315316","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T14:10:00Z","timestamp":1097590200000},"page":"563-569","source":"Crossref","is-referenced-by-count":79,"title":["Pharmacokinetics of chlorpromazine and key metabolites"],"prefix":"10.1007","volume":"45","author":[{"given":"P. K. -F.","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. D.","family":"Korchinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. K.","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0021-9673(00)85556-9","volume":"75","author":"P Turano","year":"1973","unstructured":"Turano P, Turner WJ, Manian AA (1973) Thin-layer chromatography of chlorpromazine metabolites. Attempt to identify each of the metabolites appearing in the blood, urine and feces of chronically medicated schizophrenics. J Chromatogr 75: 277?293","journal-title":"J Chromatogr"},{"key":"CR2","first-page":"275","volume-title":"Phenothiazines and structurally related drugs: Basic and clinical studies","author":"JE Kleinmann","year":"1980","unstructured":"Kleinmann JE, Bigelow LB, Rogol A, Weinberger DR, Nasrallah HA, Wyatt RJ, Gillin JC (1980) A clinical trial of 7-hydroxy-chlorpromazine in chronic schizophrenia. In: Usdin E, Eckert H, Forrest IS (ed) Phenothiazines and structurally related drugs: Basic and clinical studies, Elsevier, Amsterdam New York Oxford, pp 275?278"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00422102","volume":"26","author":"H Nyback","year":"1972","unstructured":"Nyback H, Sedvall G (1972) Effect of chlorpromazine and some of its metabolites on synthesis and turnover of catecholamines formed from 14C-tyrosine in mouse brain. Psychopharmacologia (Berl) 26: 155?160","journal-title":"Psychopharmacologia (Berl)"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00007691-198204000-00005","volume":"4","author":"SG Dahl","year":"1982","unstructured":"Dahl SG (1982) Active metabolites of neuroleptic drugs: Possible contribution to therapeutic and toxic effects. Ther Drug Monit 4: 33?40","journal-title":"Ther Drug Monit"},{"key":"CR5","first-page":"409","volume":"21","author":"SG Dahl","year":"1982","unstructured":"Dahl SG, Hjorth M, Hough E (1982) Chlorpromazine, methotrimeprazine and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulforxidation. Mol Pharmacol 21: 409?414","journal-title":"Mol Pharmacol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/00498259009046817","volume":"20","author":"TJ Jaworski","year":"1990","unstructured":"Jaworski TJ, Hawes EM, McKay G, Midha KK (1990) The metabolism of chlorpromazine N-oxide in man and dog. Xenobiotica 20: 107?115","journal-title":"Xenobiotica"},{"key":"CR7","volume-title":"Progress in drug metabolism","author":"A Jorgensen","year":"1986","unstructured":"Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism. Taylor and Francis, London Philadelphia"},{"key":"CR8","first-page":"121","volume":"4","author":"JCK Loo","year":"1980","unstructured":"Loo JCK, Midha KK, McGilveray IJ (1980) Pharmacokinetics of chlorpromazine in normal volunteers. Commun Psychopharmacol 4: 121?129","journal-title":"Commun Psychopharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2165\/00003088-197803010-00002","volume":"3","author":"TB Cooper","year":"1978","unstructured":"Cooper TB (1978) Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 3: 14?38","journal-title":"Clin Pharmacokinet"},{"key":"CR10","first-page":"443","volume":"13","author":"T Inaba","year":"1985","unstructured":"Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443?448","journal-title":"Drug Metab Dispos"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/0006-2952(85)90533-7","volume":"34","author":"C Bahr von","year":"1985","unstructured":"von Bahr C, Spina E, Birgersson C, Ericsson O, Goransson M, Henthorn T, Sjoqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34: 2501?2505","journal-title":"Biochem Pharmacol"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1016\/0006-2952(88)90063-9","volume":"37","author":"R Fonne-Pfister","year":"1988","unstructured":"Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine\/sparteine polymorphism. Biochem Pharmacol 37: 3829?3835","journal-title":"Biochem Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.1991.22","volume":"49","author":"C Bahr von","year":"1991","unstructured":"von Bahr C, Movin G, Nordin C, Liden A, Hammerland-Udenaes M, Hedberg A, Ring H, Sjoqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49: 234?240","journal-title":"Clin Pharmacol Ther"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.1989.109","volume":"46","author":"M-L Dahl-Puustinen","year":"1989","unstructured":"Dahl-Puustinen M-L, Liden A, Alm C, Nordin RN, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 46: 78?81","journal-title":"Clin Pharmacol Ther"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00316110","volume":"39","author":"JW Meyer","year":"1990","unstructured":"Meyer JW, Woggon B, Baumann P, Meyer UA (1990) Clinical implication of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39: 613?614","journal-title":"Eur J Clin Pharmacol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00266363","volume":"42","author":"E Spina","year":"1992","unstructured":"Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP (1992) Polymorphic debrisoquine oxidation and acute neuroleptic-induced side effects. Eur J Clin Pharmacol 42: 347?348","journal-title":"Eur J Clin Pharmacol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2125.1986.tb02969.x","volume":"22","author":"CJ Speirs","year":"1986","unstructured":"Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquin. Br J Pharmacol 22: 739?743","journal-title":"Br J Pharmacol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/clinchem\/25.1.166","volume":"25","author":"KK Midha","year":"1979","unstructured":"Midha KK, Loo JCK, Hubbard JW, Rowe ML, McGilveray IJ (1979) Radioimmunoassay for chlorpromazine in plasma. Clin Chem 25: 166?168","journal-title":"Clin Chem"},{"key":"CR19","first-page":"833","volume":"226","author":"PKF Yeung","year":"1983","unstructured":"Yeung PKF, Hubbard JW, Cooper JK, Midha KK (1983) A study of the kinetics of chlorpromazine sulfoxide by a specific radioimmunoassay after a single dose of chlorpromazine in healthy volunteers. J Pharmacol Exp Ther 226: 833?838","journal-title":"J Pharmacol Exp Ther"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jps.2600761011","volume":"76","author":"PKF Yeung","year":"1987","unstructured":"Yeung PKF, Hubbard JW, Korchinski ED, Midha KK (1987) Radioimmunoassay for the N-oxide metabolite of chlorpromazine in human plasma and its application to a pharmacokinetic study in healthy humans. J Pharm Sci 76: 803?808","journal-title":"J Pharm Sci"},{"key":"CR21","first-page":"816","volume":"233","author":"PKF Yeung","year":"1985","unstructured":"Yeung PKF, McKay G, Ramshaw IA, Hubbard JW, Midha KK (1985) A comparison of two radioimmunassays for 7-hydroxy-chlorpromazine: rabbit polyclonal antibodies vs mouse monoclonal antibodies. J Pharmacol Exp Ther 233: 816?822","journal-title":"J Pharmacol Exp Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00007691-198709000-00018","volume":"9","author":"KK Midha","year":"1987","unstructured":"Midha KK, Hubbard JW, Cooper JK, Gurnsey T, Hawes EM, McKay G, Chakraborty BS, Yeung PKF (1987) Therapeutic monitoring of chlorpromazine IV: comparison of a new high performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites. Ther Drug Monit 9: 358?365","journal-title":"Ther Drug Monit"},{"key":"CR23","volume-title":"Basic Pharmacokinetics","author":"WA Ritschel","year":"1986","unstructured":"Ritschel WA (1986) Basic Pharmacokinetics. Drug Intelligence Publications, Hamilton"},{"key":"CR24","first-page":"474","volume":"10","author":"KK Chan","year":"1982","unstructured":"Chan KK (1982) A simple and integrated method for drug and derived metabolite kinetics. An application of the statistical moment theory. Drug Metab Dispos 10: 474?479","journal-title":"Drug Metab Dispos"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jps.2600820205","volume":"82","author":"KK Midha","year":"1993","unstructured":"Midha KK, Ormsby ED, Hubbard JW, McKay G, Hawes EM, Gavalas L, McGilveray IJ (1993) Logarithmic transformation in bioequivalence: application with two formulations of perphenazine. J Pharm Sci 82: 138?144","journal-title":"J Pharm Sci"},{"key":"CR26","doi-asserted-by":"crossref","DOI":"10.1201\/b14095","volume-title":"Pharmacokinetics","author":"M Gibaldi","year":"1982","unstructured":"Gibaldi M, Perrier D (1982) Pharmacokinetics. Dekker, New York"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/cpt1977214437","volume":"21","author":"SG Dahl","year":"1976","unstructured":"Dahl SG, Strandjord RE (1976) Pharmacokinetics of chlorpromazine after single and chronic doses. Clin Pharmacol Ther 21: 437?448","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00315316\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315316","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T12:37:29Z","timestamp":1624711049000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00315316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1993,12]]}},"alternative-id":["BF00315316"],"URL":"https:\/\/doi.org\/10.1007\/bf00315316","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,12]]}}}